RxDoctor Payments Data

Allison Doyle

Family · Pasadena, MDNPI 1184309254

Payments from drug & device makers

$1,490in general payments, 2019–2025

Across 55 payments — averaging $27.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$256
  • Novo Nordisk$207
  • Corcept Therapeutics$166
  • Sanofi-aventis U.S. LLC$136
  • Lilly USA, LLC$130
  • Astellas Pharma US Inc$74
  • plus $521 from 16 others

What the payments were for

  • Food & beverage$1,490100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,490 in reported general payments places this provider in the 75th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$24,371
Medicare patients
164
Services billed
335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin15$17,399
Atorvastatin Calcium87$1,637
Rosuvastatin Calcium42$1,349
Metoprolol Succinate59$1,339
Ezetimibe12$1,082
Losartan Potassium53$870
Amlodipine Besylate95$809
Escitalopram Oxalate31$698
Omeprazole28$685
Albuterol Sulfate HfaAlbuterol Sulfate35$684
Levothyroxine Sodium44$513
Metformin Hcl ErMetformin Hcl22$430
Pravastatin Sodium23$427
SynthroidLevothyroxine Sodium12$403
Lisinopril52$376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$19$17,39915 claims
AbbVieSynthroid$256$40312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,843 family providers in Maryland.

Other family in Pasadena

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →